Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
(2017) In Journal of Clinical Medicine 6(2).- Abstract
Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated and/or T cell-mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second-line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy.... (More)
Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated and/or T cell-mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second-line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, thirdline treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms.
(Less)
- author
- Zufferey, Anne ; Kapur, Rick LU and Semple, John W LU
- organization
- publishing date
- 2017-02-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- immune thrombocytopenia (ITP), autoimmunity, T cells, B cells, platelets
- in
- Journal of Clinical Medicine
- volume
- 6
- issue
- 2
- pages
- 21 pages
- publisher
- MDPI AG
- external identifiers
-
- scopus:85067220122
- pmid:28208757
- ISSN
- 2077-0383
- DOI
- 10.3390/jcm6020016
- language
- English
- LU publication?
- yes
- id
- f2e314b1-881e-4bb1-8640-59beb37ad4d0
- date added to LUP
- 2022-11-09 15:21:29
- date last changed
- 2024-04-19 21:00:42
@article{f2e314b1-881e-4bb1-8640-59beb37ad4d0,
abstract = {{<p>Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated and/or T cell-mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second-line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, thirdline treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms.</p>}},
author = {{Zufferey, Anne and Kapur, Rick and Semple, John W}},
issn = {{2077-0383}},
keywords = {{immune thrombocytopenia (ITP); autoimmunity; T cells; B cells; platelets}},
language = {{eng}},
month = {{02}},
number = {{2}},
publisher = {{MDPI AG}},
series = {{Journal of Clinical Medicine}},
title = {{Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)}},
url = {{http://dx.doi.org/10.3390/jcm6020016}},
doi = {{10.3390/jcm6020016}},
volume = {{6}},
year = {{2017}},
}